Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium: The Takeda Oncology Company and Seattle Genetics have released data from two dose-escalation Phase I trials evaluating Adcetris (Brentuximab Vedotin) in patients with relapsed or refractory Hodgkin lymphoma.
Subscribe to our email newsletter
Adcetris is an antibody-drug conjugate (ADC) constituting an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a synthetic drug, monomethyl auristatin E (MMAE) using Seattle Genetics’ proprietary technology.
In the trails, 20 relapsed or refractory Hodgkin lymphoma patients who were ineligible for or refused treatment with ASCT were among patients enrolled in two phase I dose-escalation trials of Adcetris conducted from 2006 to 2010.
Six out of 20 patients achieved an objective response, including two complete remissions and four partial remissions.
The two patients who attained complete remission maintained their remission after 10.7 and 13.8 months of follow-up, respectively.
Seattle Genetics chief medical officer Thomas Reynolds said these data from their Phase I trials support the activity and tolerability of Adcetris in patients for whom standard second-line induction therapy is not an option or has failed to produce a robust response prior to ASCT.
Under the terms of a collaboration agreement, Seattle Genetics has the US and Canadian commercialization rights and the Takeda Group has rights to commercialize Adcetris in the rest of the world.
Seattle Genetics and the Takeda Group are funding joint development costs for Adcetris on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.